Reddit Posts
$DERM Is a solid candidate for a squeeze and acquisition
DERM – Journey Medical | Profitable Derm Pharma at 2.9x P/S | 9-Day Short Cover | Wasatch 10% | May Earnings Catalyst | Full DD
DERM seems to be a strong candidate for a squeeze
DONT SLEEP ON $DERM. I believe we’ll see at least $100 by the end of 2026!!!
Outlook on Journey Medical Corp ($DERM)?
Finding Gems in the Biotech Rough: $ATXI, $CKPT, $DERM, $DSS, $FBIO, $MBIO
Finding Gems in the Biotech Rough: $ATXI, $CKPT, $DERM, $DSS, $FBIO, $MBIO
Mentions
Also long DERM. I feel like the size of this company has prevented investor visibility into the multiple positive aspects in your original post. I am excited for the 2Q results. Maybe the shorts will finally be humbled into submission.
https://preview.redd.it/vx75mn3m37yf1.jpeg?width=1170&format=pjpg&auto=webp&s=35e56d30bfeafcba0c11008d35df4f33c8536e6e Isn’t this good news for FBIO and DERM?
A combination of things: 1. The nature of their business is quite complicated (multiple private subsidiaries, some of which have out-licenced parts of their pipeline) making it hard to value at first glance. 2. One of their biggest subsidiaries was Checkpoint, which got hit with a CRL in late 2023, which set back one of their big revenue sources. They later got approval in 2024 and were sold off this year which bolstered the balance sheet, but I think confidence took a bit of a hit with the delay. 3. There are 2 classes of shares, the Preferred shares pay a perpetual dividend (costs about 600k per month) but it has been paused since last July. While these distributions are paused, the company can't raise cash via offerings under S-3. They also have some debt. 4. Biotechs under 100M mc just don't get a lot of love! However. This all said, the number I gave was net of debt. They have bolstered their balance sheet, and if CUTX-101 is approved and the PRV is awarded, that is a huge income and will make it very likely for FBIOP dividend to be restored (it is also a requirement that the debt is paid off via proceeds of the PRV sale). So this would significantly improve confidence, and also (the bit I didn't mention) buy a significant amount of time for DERM's launch of Emrosi to gather pace and tip them into profitability (projected to happen later this year). I think upon achieving a tidier capital structure and more cash in the bank, the market will take a more appropriate valuation.
The current market cap hasn't even priced in the full value of company's cash and ownership of publicly listed stocks (FBIO is like a small fund, it has stakes in a variety of biotech companies including about 42% of DERM). Just to reach a 1x assets valuation, it needs to hit a price if about $2.80
DERM (Journey Medical Corp) they have a portfolio of 7-8 smaller dermatology products that have brought them to almost breakeven (Net loss about 4M last quarter). Then, just this March have launched their new flagship rosacea product, which is expected to reach peak sales of 100-200M dollars in the next 3 years. This new product achieved 2.1M revenue in roughly first week of sales. Because they already had a strong dermatology sales force and no further R&D pipeline, all the launch expense has taken place and pretty much all new sales will drop straight to the bottom line. So I am expecting them to tip into small profit in the upcoming Q2 earnings then strong growth over the next 2 years. Current market cap 113M, with Q1 revenue 13.1M, 21M cash on hand.
CAPR and DERM CAPR for the Muscular Dystrophy drug under FDA review currently, expecting an announvemnet of acceptance of data in the next 3 weeks or so then a scheduled PDUFA by end of August. Ground breaking. DERM- conference call at 4:30 est. Have a standard of care drug just recently approved on Nov 4th 2024 and is going to impact SP by 3-4x+ within 2 years and possibly a whole lot sooner
DERM/FBIO went down after PDUFA full approval for a rosacea medicine. CKPT is likely to be greenlit as they’ve had longer term data to strengthen their already strong case (FDA said data is good, just fix the manufacturing issue with the lab). Same issue happened to another biotech with a PDUFA date of Dec 26th of this year. They were approved early last week. NFA, but if you want this long term, don’t wait for it to drop into the low 3’s. The 2.17 price is long gone for now unless it does a weird thing like FBIO/DERM.
Your post with title "FBIO/ DERM PR - Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea" has been automatically removed from r/PennyStocks for being low-effort/spam. (Low word count) probably by u/automod *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
DERM (Journey Medical) is supposed to get FDA approval on their new drug in 7 days. Could we see a spike? Target is 9$
I'm in for 700 Shares of $DERM......Let it ride a couple weeks. ​ https://preview.redd.it/7zk76vt0la7c1.png?width=613&format=png&auto=webp&s=f335423630515c78c1bd2994eeeacb6fe90f66a1
DERM, low float 11m , insiders own 60%, recent IPO, and just broke out of a downtrend